Calquence (acalabrutinib) / AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Calquence (acalabrutinib) / AstraZeneca
ACE-LY-002, NCT02112526: Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Active, not recruiting
1
21
Europe, US
Acalabrutinib, ACP-196
Acerta Pharma BV
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
06/20
04/26
ACE-CL-002, NCT02157324: Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Hourglass Jul 2020 - Dec 2020 : From trial in r/r CLL
Active, not recruiting
1
12
US
acalabrutinib, ACP-196, ACP-319
Acerta Pharma BV
Chronic Lymphocytic Leukemia
07/20
04/26
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Active, not recruiting
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
09/27
NCT03328273 / 2016-003737-15: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Hourglass Jan 2021 - Jun 2021 : Data from P1 part of P1/2 trial in combination with AZD6738 for r/r CLL
Hourglass Jan 2021 - Jun 2021 : Data from P1 portion of P1/2 trial in combination with Calquence in r/r CLL
Active, not recruiting
1
11
Europe
Ceralasertib, AZD6738, Acalabrutinib, ACP196
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/21
08/26
NCT05404282: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
1
11
Europe
Ceralasertib, AZD6738, Acalabrutinib, ACP196
AstraZeneca
Chronic Lymphocytic Leukemia
09/21
06/23
ACE-LY-106, NCT02717624: A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Checkmark Data from P1b trial for MCL
Nov 2022 - Nov 2022: Data from P1b trial for MCL
Active, not recruiting
1
72
Europe, US
Acalabrutinib in combination with BR, Acalabrutinib + BR, Acalabrutinib in combination with VR, Acalabrutinib + VR
Acerta Pharma BV, AstraZeneca
Mantle Cell Lymphoma (MCL)
06/22
08/27
NCT03198650: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Hourglass Jul 2022 - Dec 2022 : Data from P1 tria for advanced B-cell malignancies
Checkmark In B-cell malignancies in Japanese adults
Mar 2021 - Mar 2021: In B-cell malignancies in Japanese adults
Active, not recruiting
1
35
Japan
Acalabrutinib, Obinutuzumab
AstraZeneca
Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
10/22
12/24
NCT04462328: Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Recruiting
1
21
US
Durvalumab, Imfinzi, Acalabrutinib, Calquence
Washington University School of Medicine, AstraZeneca
Primary Central Nervous System Lymphoma
03/26
12/27
NCT04688151: Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Recruiting
1
22
RoW
Rituximab, Acalabrutinib, Durvalumab
National Health Research Institutes, Taiwan, National Taiwan University Hospital, National Cheng-Kung University Hospital, China Medical University Hospital, Chang Gung Memorial Hospital
Primary Central Nervous System Lymphoma (PCNSL)
12/25
12/25
NCT05943496: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Recruiting
1
25
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Chronic Lymphocytic Leukemia
01/26
01/27
NCT05971251: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Loncastuximab Tesirine and Acalabrutinib
Mayur Narkhede, ADC Therapeutics S.A.
Chronic Lymphocytic Leukemia
12/26
12/28
NCT05495464: A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Recruiting
1
20
US
Acalabrutinib, Rituximab, Rituxan, Brexucabtagene Autoleucel, Cyclophosphamide, Cytoxan®, Neosar®, Fludarabine Phosphate, Fludarabine, Fludara®
M.D. Anderson Cancer Center, Kite, A Gilead Company, Acerta Pharma, LLC
Lymphoma, Mantle Cell Lymphoma
03/27
03/27
NCT05983965: Study of Tazemetostat in Lymphoid Malignancies

Recruiting
1
30
US
Tazemetostat
University of Alabama at Birmingham
T-cell Lymphoma
07/28
12/29

Download Options